# Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension

> **NCT01193101** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 389 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** LCZ696
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01193101
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 389 (ACTUAL)
- **Last updated:** 2016-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01193101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01193101, "Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01193101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*